CN101090711A - 治疗肺部感染的颗粒 - Google Patents

治疗肺部感染的颗粒 Download PDF

Info

Publication number
CN101090711A
CN101090711A CNA2005800449753A CN200580044975A CN101090711A CN 101090711 A CN101090711 A CN 101090711A CN A2005800449753 A CNA2005800449753 A CN A2005800449753A CN 200580044975 A CN200580044975 A CN 200580044975A CN 101090711 A CN101090711 A CN 101090711A
Authority
CN
China
Prior art keywords
formulation
particles
capreomycin
nanoparticles
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800449753A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·A·爱德华兹
珍妮弗·菲格尔
琼·孙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of CN101090711A publication Critical patent/CN101090711A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA2005800449753A 2004-10-29 2005-10-19 治疗肺部感染的颗粒 Pending CN101090711A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62373804P 2004-10-29 2004-10-29
US60/623,738 2004-10-29

Publications (1)

Publication Number Publication Date
CN101090711A true CN101090711A (zh) 2007-12-19

Family

ID=37667331

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800449753A Pending CN101090711A (zh) 2004-10-29 2005-10-19 治疗肺部感染的颗粒

Country Status (11)

Country Link
US (1) US8846607B2 (enExample)
EP (1) EP1809252A2 (enExample)
JP (1) JP2008518007A (enExample)
CN (1) CN101090711A (enExample)
AU (1) AU2005334514B2 (enExample)
BR (1) BRPI0517374A (enExample)
CA (1) CA2585859C (enExample)
IL (1) IL182785A0 (enExample)
RU (1) RU2007119721A (enExample)
WO (1) WO2007011396A2 (enExample)
ZA (1) ZA200703452B (enExample)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225058A (zh) * 2011-06-22 2011-10-26 中国药科大学 磷酸奥司他韦吸入粉雾剂及其制备方法
CN108697790A (zh) * 2015-09-03 2018-10-23 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
CN113907360A (zh) * 2021-07-30 2022-01-11 湖南达侑科技有限公司 植物甾醇磷脂组合物及其制备方法
US11278612B2 (en) 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN117083063A (zh) * 2020-05-14 2023-11-17 兴和株式会社 新型吸入剂
CN117083278A (zh) * 2021-02-01 2023-11-17 结核病药物开发全球联盟公司 普托马尼无定形形式
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
US12357684B2 (en) 2008-12-09 2025-07-15 Novavax, Inc. Modified RSV F proteins and methods of their use

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2399385C1 (ru) * 2009-03-10 2010-09-20 Общество с ограниченной ответственностью "Научно-производственная фирма "НОРД" Способ профилактической обработки животных и птиц
JP2012524817A (ja) * 2009-04-24 2012-10-18 シェーリング コーポレイション 標的粒子サイズを有する、活性医薬を含む凝集体配合物
US20120076838A1 (en) * 2009-05-27 2012-03-29 Samyang Biopharmaceuticals Corporation Poorly soluble drug containing microsphere with improved bioavailabilty and method of preparing the same
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
KR20140147891A (ko) * 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
RU2562550C2 (ru) * 2013-12-19 2015-09-10 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт бруцеллеза и туберкулеза животных" (ФГБНУ ВНИИБТЖ) Способ специфической профилактики туберкулеза
WO2018226949A1 (en) 2017-06-08 2018-12-13 Pai Life Sciences Inc. Cpzen compositions and uses
EA202190331A1 (ru) * 2018-07-24 2021-06-17 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки
BR112022022243A2 (pt) * 2020-05-01 2022-12-20 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Bloqueadores do canal de proteína e e inibidores de orf3 como agentes anti-covid-19.
JPWO2022044582A1 (enExample) * 2020-08-28 2022-03-03
JP2024049405A (ja) * 2021-02-22 2024-04-10 興和株式会社 新規吸入剤

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) * 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
IT1228459B (it) * 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
IS1796B (is) 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
JP2930421B2 (ja) * 1994-02-28 1999-08-03 メディノヴァ メディカル コンサルティング ゲゼルシャフト ミット ベシュレンクテル ハフツング 薬剤組成物、その製造方法及びその使用方法
DE69535897D1 (de) * 1994-03-07 2009-01-22 Nektar Therapeutics Verfahren und Zusammensetzung für die pulmonale Darreichung von Insulin
US5814617A (en) * 1994-10-07 1998-09-29 The United States Of America As Represented By The Secretary Of The Navy Protective 17 KDA malaria hepatic and erythrocytic stage immunogen and gene
DK0752245T3 (da) 1995-07-05 2002-09-09 Europ Economic Community Biokompatible og bionedbrydelige nanopartikler udviklet til absorption og afgivelse af proteinholdige lægemidler
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US20020052310A1 (en) 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6586008B1 (en) * 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
DE60025019T2 (de) * 1999-10-29 2006-08-24 Nektar Therapeutics, San Carlos Trockenpulverzusammensetzungen mit verbesserter dispersivität
US6766799B2 (en) * 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
WO2003043586A2 (en) * 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
WO2004024213A2 (en) * 2002-09-12 2004-03-25 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services Aerosolized capreomycin for inhibition of pulmonary tuberculosis
CN1694689A (zh) * 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12357684B2 (en) 2008-12-09 2025-07-15 Novavax, Inc. Modified RSV F proteins and methods of their use
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
CN102225058A (zh) * 2011-06-22 2011-10-26 中国药科大学 磷酸奥司他韦吸入粉雾剂及其制备方法
CN108697790A (zh) * 2015-09-03 2018-10-23 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
US11253585B2 (en) 2015-09-03 2022-02-22 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US12257297B2 (en) 2015-09-03 2025-03-25 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
CN109260180A (zh) * 2017-07-17 2019-01-25 北京盈科瑞创新药物研究有限公司 一种盐酸莫西沙星雾化吸入用溶液制剂及其制备方法
US12083228B2 (en) 2017-07-24 2024-09-10 Novavax, Inc. Methods and compositions for treating respiratory disease
US11896662B2 (en) 2018-03-19 2024-02-13 Novavax, Inc. Multivalent influenza nanoparticle vaccines
US11278612B2 (en) 2018-03-19 2022-03-22 Novavax, Inc. Multivalent influenza nanoparticle vaccines
CN117083063A (zh) * 2020-05-14 2023-11-17 兴和株式会社 新型吸入剂
CN117083278A (zh) * 2021-02-01 2023-11-17 结核病药物开发全球联盟公司 普托马尼无定形形式
CN113907360A (zh) * 2021-07-30 2022-01-11 湖南达侑科技有限公司 植物甾醇磷脂组合物及其制备方法

Also Published As

Publication number Publication date
WO2007011396A2 (en) 2007-01-25
BRPI0517374A (pt) 2008-10-07
EP1809252A2 (en) 2007-07-25
JP2008518007A (ja) 2008-05-29
ZA200703452B (en) 2008-06-25
US8846607B2 (en) 2014-09-30
RU2007119721A (ru) 2008-12-10
US20080213373A1 (en) 2008-09-04
AU2005334514A1 (en) 2007-01-25
CA2585859A1 (en) 2007-01-25
CA2585859C (en) 2012-03-06
IL182785A0 (en) 2007-09-20
WO2007011396A3 (en) 2007-05-03
AU2005334514B2 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
ZA200703452B (en) Particles for treatment of pulmonary infection
US9439862B2 (en) Phospholipid-based powders for drug delivery
US7442388B2 (en) Phospholipid-based powders for drug delivery
US8668934B2 (en) Pharmaceutical formulation comprising a water-insoluble active agent
JP5727927B2 (ja) フルオロキノロンの肺送達
PT2630954T (pt) Administração pulmonar de levodopa
AU2020203437B2 (en) Dry powder formulations for inhalation
US20080089849A1 (en) Powders for inhalation
CN111228244A (zh) 一种利巴韦林吸入制剂及其在制备治疗新冠肺炎中的用途
MX2007005139A (es) Particulas para el tratamiento de infeccion pulmonar
Kraft et al. Preparation of macromolecule-containing dry powders for pulmonary delivery
CN118845721A (zh) 可吸入团聚纳米颗粒干粉药物组合物、及其制备方法和用途
HK40116441A (en) Inhalable agglomerated nanoparticle dry powder pharmaceutical compositions, methods of making and use thereof
Kumar et al. Spray Dried Particles for Inhalation
HK1240081B (en) Dry powder formulations for inhalation
HK1240081A1 (en) Dry powder formulations for inhalation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20071219